-
Analysts Shrug Off Softness In Edwards Lifesciences' Heart Value Replacement System
Wednesday, April 24, 2019 - 11:22am | 727Read More...Edwards Lifesciences Corp (NYSE: EW) reported Tuesday after the market close with above-consensus first-quarter results and raised its adjusted earnings per share guidance for the full year. The Analysts UBS analyst Matthew Taylor maintained a Neutral rating on Edwards with a $190...
-
No Reason To Believe Intuitive Surgical's Momentum Will Stop Now
Friday, July 21, 2017 - 10:43am | 402Read More...Barclays analyst Matthew Taylor reiterated an Overweight rating on Intuitive Surgical, Inc. (NASDAQ: ISRG) with a price target upped to $1,000. Although Intuitive slightly missed the Street’s EPS estimate for the second quarter, it easily beat on sales. Taylor noted “robust”...
-
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
Thursday, October 20, 2016 - 1:41pm | 256Read More...Barclays believes investors are underestimating St. Jude Medical, Inc. (NYSE: STJ)’s pipeline and growth potential in future periods as it is working to close its merger with Abbott Laboratories (NYSE: ABT) in the fourth quarter. The brokerage noted that the merger synergies are...
-
Barclays Praises Impressive Q3 From Intuitive Surgical
Wednesday, October 19, 2016 - 11:58am | 290Read More...Reviewing Intuitive Surgical, Inc.'s (NASDAQ: ISRG) third quarter results, Barclays commended the company for another solid beat, with strong capital/procedure growth and margin outperformance. Analyst Matthew Taylor noted that the company's revenues rose 16 percent year-over-year and...
-
Barclays Bullish On Baxter International, $52 Price Target
Thursday, September 15, 2016 - 10:54am | 239Read More...Barclays reinstated coverage of Baxter International Inc (NYSE: BAX) with an Overweight rating and $52 price target as it sees upside to long-term growth and margin targets. Since spinning off the Baxalta biopharma business in May 2015, the company has delivered a series of beats and raises due...
-
Rising Street Value Of ResMed Shares Disconnected From Its Fundamentals
Thursday, August 25, 2016 - 11:30am | 317Read More...The stock valuation for ResMed Inc. (NYSE: RMD) and its share price have increased despite the company’s deteriorating fundamentals. Barclays’ Matthew Taylor maintained an Underweight rating on the company, with a price target of $55. Headwinds “While sleep apnea is a good...
-
Barclays Says Investors Underestimate St. Jude Medical 's Potential
Friday, August 12, 2016 - 12:41pm | 309Read More...Barclays said investors are underestimating St. Jude Medical, Inc.'s (NYSE: STJ) pipeline and growth potential in future periods as the addition of St. Jude will make Abbott Laboratories (NYSE: ABT) a leader in the Medical Devices business. Late April, Abbott agreed to buy St. Jude for...
-
Barclays Ups C.R. Bard's Price Target By $11
Wednesday, July 27, 2016 - 2:05pm | 343Read More...Barclays raised its earnings estimate and price target for C R Bard Inc (NYSE: BCR), premising the actions on the company's second-quarter earnings and revenue beat. The firm noted that the second-quarter outperformance came about due to new product launches, 20 percent growth in emerging markets...
-
Barclays Bullish On Intuitive Surgical On Heels Of Earnings Report
Wednesday, July 20, 2016 - 9:16am | 367Read More...Intuitive Surgical, Inc. (NASDAQ: ISRG) reported robust quarterly reports, with the revenue and EPS beating the consensus expectations. Barclays’ Matthew Taylor maintains an Overweight rating on the company, while raising the price target from $690 to $750. Beat Quarter Intuitive Surgical...
-
Abbott Laboratories Is 'A Premium Asset At A Discount,' Says Barclays
Monday, July 11, 2016 - 9:48am | 320Read More...Without specifically commenting on 2Q, Abbott Laboratories (NYSE: ABT) management indicated that they were bullish about the future prospects of the businesses, Barclays’ Matthew Taylor said in a report. He maintained an Overweight rating for the company, with a price target of $48....
-
Intuitive Surgical's Da Vinci Prostatectomy Bolus 'Has Legs,' Barclays Says
Friday, June 17, 2016 - 5:10pm | 296Read More...Barclays reiterated its Overweight rating on Intuitive Surgical, Inc. (NASDAQ: ISRG) after its urologist survey showed that da Vinci Prostatectomy (dVP) bolus has legs and the numbers are achievable. "Based on physician feedback and our math, we think this bolus will last at least through...
-
Barclays Likes Abbott Laboratories, Whether Acquisitions Close Or Not
Friday, June 17, 2016 - 5:09pm | 353Read More...Barclays analyst Matthew Taylor likes Abbott Laboratories (NYSE: ABT) irrespective of whether the company closes their acquisitions of Alere Inc (NYSE: ALR) and St. Jude Medical, Inc. (NYSE: STJ). The brokerage reiterated its Overweight rating and $48.00 price objective on Abbott shares. The...
-
Barclays Sees Upside In Teleflex, Raises Price Target
Tuesday, June 14, 2016 - 9:16am | 149Read More...Barclays' Matthew Taylor reiterated Telefex Incorporated (NYSE: TFX) at Overweight, raising the price target to $183.00. The price objective change came after the analyst met with management last week. Related Link: Teleflex Sees FY2016 Guidance $7.10 To $7.25 "The TFX business appears healthy,"...
-
Barclays Bullish On NuVasive, Globus Medical, Dislikes LDR Holding
Friday, May 27, 2016 - 9:36am | 458Read More...Barclays’ Matthew Taylor expanded the spine coverage to include Globus Medical Inc (NYSE: GMED) and LDR Holding Corp (NASDAQ: LDRH), saying that these were “pure play innovators,” while upgrading the rating for NuVasive, Inc. (NASDAQ: NUVA). NuVasive Analyst Matthew Taylor...
-
Barclays Upgrades Abbott, Sees 'Selling Overdone'
Wednesday, October 7, 2015 - 8:28am | 296Read More...Shares of Abbott Laboratories (NYSE: ABT) have declined 19.8 percent over the last three months, hitting a low of $39.06 on September 28. Barclays’ Matthew Taylor has upgraded the rating from Equal Weight to Overweight, while lowering the price target from $55 to $52. Taylor...
